Side effects of ketamine in the long-term treatment of neuropathic pain

Pain Medicine

Volumn 9, Issue 2, 2008, Pages 253-257

  Cvrček, Petr ^a  

^a Hospital Jihlava   (Czech Republic)

Author keywords

Chronic pain; Ketamine; Neuropathic pain; NMDA receptor

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DIHYDROCODEINE; KETAMINE; OPIATE;

ANOREXIA; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; DIABETIC NEUROPATHY; DIZZINESS; DROWSINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EEG ABNORMALITY; FEMALE; HALLUCINATION; HEART RATE; HUMAN; LONG TERM CARE; MALE; MEMORY DISORDER; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; POSTHERPETIC NEURALGIA; PROSPECTIVE STUDY; SALIVATION; SEDATION; SIDE EFFECT; SYMPATHETIC TONE; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; ANALGESICS; DIABETIC NEUROPATHIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; NAUSEA; NEURALGIA; PAIN MEASUREMENT; PATIENT SELECTION; PROSPECTIVE STUDIES; TIME FACTORS; VOMITING;

EID: 39649102928     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2007.00314.x     Document Type: Article

References (18)

1. Larsen R. Anestezie, 5th edition. Prague: Grada Publishing; 1998.
2. Clubb B. Management of neuropathic pain following treatment for breast cancer in the absence of recurrence: A challenge for the radiation oncologist. Australas Radiol 2004;48:459-65.
3. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997;333:99-104.
4. Eide P, Jorum E, Stubhaug A, Bremnes J, Breivit H. Relief of postherpetic neuralgia with the NMDA receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placebo. Pain 1994;58:347-54.
5. Eide P, Stubhaug A, Breivit H. Continuous subcutaneous administration of the NMDA receptor antagonist ketamine in the treatment of postherpetic neuralgia. Pain 1995;61:221-8.
6. Eide PK, Stubhaug A. Relief of glossopharyngeal neuralgia by ketamine-induced N-Methyl-aspartate Receptor Blockade. Neurosurgery 1997;41:505-8.
7. Finnerup NB, Johannesen IL, Sindrep SH, Bach FW, Jensen TS. Pain and dysesthesia in patients with spinal cord injury. A postal survey. Spinal Cord 2001;39:256-62.
8. Fitzgibbon EJ, Hall P, Schroder C, Seely J, Viola R. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: A strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage 2002;23:165-70.
9. Fitzgibbon EJ, Viola R. Parenteral ketamine as an analgesic adjuvant for severe pain: Development and retrospective audit of a protocol for a palliative care unit. J Palliat Med 2005;8:49-57.
10. Hoffmann V, Coppejans H, Vercauteren M, Adriaensen H. Successful treatment of postherpetic neuralgia with oral ketamine. Clin J Pain 1994;10:240-2.
11. Kato Y, Homma I, Ichiyanagi K. Postherpetic neuralgia. Clin J Pain 1995;11:336-8.
12. Stannard C, Porter G. Ketamine hydrochloride in the treatment of phantom limb pain. Pain 1993;54:227-30.
13. Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE. Subanesthetic ketamine infusion therapy: A retrospoctive analysis of a novel therapeutic approach to komplex regional pain syndrome. Pain Med 2004;5(3):263-75.
14. Bell RF. Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain 1999;83:101-3.
15. Grant I, Nimmo W, Clements J. Pharmacokinetics and analgesic effects of IM and oral ketamine. Br J Anaesth 1981;53:805-10.
16. Dundee JW, Fee JPH, McIlory PDA, Wilson DB. Changes in serum enzyme levels following ketamine infusion. Anesthesia 1980;35:12-6.
17. Kress HG. Wirkungsmechanismen von Ketamin. Anaesthesist 1997;46(suppl I):8-19.
18. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: A review of current techniques and outcomes. Pain 1999;82:111-25.